ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

ClinicalTrials.gov ID: NCT06641076

Public ClinicalTrials.gov record NCT06641076. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs

Study identification

NCT ID
NCT06641076
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Enrollment
960 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sonelokimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 14, 2024
Primary completion
Feb 3, 2027
Completion
Feb 3, 2027
Last update posted
Apr 28, 2026

2024 – 2027

United States locations

U.S. sites
28
U.S. states
13
U.S. cities
28
Facility City State ZIP Site status
Clinical Site Avondale Arizona 85392
Clinical Site Chandler Arizona 85225
Clinical Site Flagstaff Arizona 86001
Clinical Site Mesa Arizona 85210
Clinical Site Phoenix Arizona 85032
Clinical Site Scottsdale Arizona 85260
Clinical Site Tucson Arizona 85748
Clinical Site San Diego California 92108
Clinical Site Upland California 91786
Clinical Site Avon Park Florida 33825
Clinical Site Clearwater Florida 33765
Clinical Site Hialeah Florida 33016
Clinical Site Tampa Florida 33607
Clinical Site Springfield Illinois 62702
Clinical Site Lake Charles Louisiana 70605
Clinical Site Baltimore Maryland 21224-6821
Clinical Site Grand Blanc Michigan 48439-2451
Clinical Site Leland North Carolina 28451
Clinical Site Salisbury North Carolina 28144
Clinical Site Statesville North Carolina 28625
Clinical Site Middleburg Heights Ohio 44130
Clinical Site Portland Oregon 97239
Clinical Site Memphis Tennessee 38119
Clinical Site Allen Texas 75013
Clinical Site Colleyville Texas 76034
Clinical Site Lubbock Texas 79424
Clinical Site Plano Texas 75024
Clinical Site Beckley West Virginia 25801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 140 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06641076, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06641076 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →